These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
Insulin injections or pumps are routine for people with type 1 diabetes, but they aren’t a cure. Teplizumab (Tzield), developed and distributed by Provention Bio and Sanofi, however, may bring us one step closer to one. The drug, which patients inject daily for 14 days, is an antibody that prevents immune cells from attacking the insulin-making cells that are important for controlling blood sugar. It’s expensive (about $193,000 for a 14-day course), but it’s the first treatment to address the actual cause of type 1 diabetes. In one study, people on the verge of developing type 1 diabetes who received the drug were able to double the time it took to get diagnosed compared to those who received placebo.
More Must-Reads from TIME
- Donald Trump Is TIME's 2024 Person of the Year
- Why We Chose Trump as Person of the Year
- Is Intermittent Fasting Good or Bad for You?
- The 100 Must-Read Books of 2024
- The 20 Best Christmas TV Episodes
- Column: If Optimism Feels Ridiculous Now, Try Hope
- The Future of Climate Action Is Trade Policy
- Merle Bombardieri Is Helping People Make the Baby Decision
